WallStSmart

Pfizer Inc (PFE)vsSpace Exploration Technologies Corp. Class A Common Stock (SPCX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 228% more annual revenue ($63.32B vs $19.30B). PFE leads profitability with a 11.8% profit margin vs -45.0%. PFE earns a higher WallStSmart Score of 55/100 (C).

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.70

SPCX

Avoid

23

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.17
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PFEUndervalued (+13.8%)

Margin of Safety

+13.8%

Fair Value

$30.21

Current Price

$26.04

$4.17 discount

UndervaluedFair: $30.21Overvalued

Intrinsic value data unavailable for SPCX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$145.62B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

SPCX2 strengths · Avg: 9.0/10
Market CapQuality
$1.77T10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
15.4%8/10

15.4% revenue growth

Areas to Watch

PFE3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

SPCX4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
27.0x2/10

Trading at 27.0x book value

Return on EquityProfitability
-11.9%2/10

ROE of -11.9% — below average capital efficiency

Free Cash FlowQuality
$-9.06B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bull Case : SPCX

The strongest argument for SPCX centers on Market Cap, Revenue Growth. Revenue growth of 15.4% demonstrates continued momentum.

Bear Case : PFE

The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.

Bear Case : SPCX

The primary concerns for SPCX are EPS Growth, Price/Book, Return on Equity.

Key Dynamics to Monitor

PFE profiles as a value stock while SPCX is a growth play — different risk/reward profiles.

SPCX is growing revenue faster at 15.4% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PFE scores higher overall (55/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Space Exploration Technologies Corp. Class A Common Stock

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Space Exploration Technologies Corp. The company is headquartered in Starbase, Texas.

Want to dig deeper into these stocks?